Led · Equity · Jul 2026

ENGO develops lightweight smart glasses for runners, cyclists, triathletes and other endurance athletes that use an integrated augmented reality Micro-OLED display to project real-time performance data into the wearer’s field of view. Its eyewear combines embedded display technology with up to 20 hours of battery life in a frame weighing less than 40 grams. The company emphasises miniaturisation, energy optimisation and optical innovation to reduce weight and make the technology unobtrusive. ENGO plans to expand its team and commercial footprint, strengthen sports-industry partnerships and pursue further R&D in display, optics and power efficiency. The company also intends to explore applications for its smart eyewear technology beyond endurance sports. It recently secured €5.1 million in funding to support these plans.

Participated · Equity · Jul 2026

Elixir Aircraft designs and manufactures carbon-fiber light aircraft aimed at flight schools and pilot training. The company has launched a new program named Equinox as part of its product roadmap. Management is pursuing an international growth strategy and began expanding into the United States shortly before this financing. Following the €45 million round, led by SPI with a €20 million contribution, Elixir plans to ramp production with a goal of delivering nearly 60 training aircraft per year by 2027. The company has previously attracted outside investors and continues to rely on external capital to scale operations.

Led · Equity · Mar 2026

Aerix Systems, founded in 2020, builds the AXS Micro, a small, highly agile aerial robot with a 40 cm wingspan, 4 kg weight and a top speed of 200 km/h. The machine can fly on its edge or back, execute abrupt direction changes and operate in winds up to 100 km/h. Aerix targets defense counter‑drone use—particularly against FPV drones—and industrial inspection on hard‑to‑reach sites. After a €1.6 million raise in 2024, the company secured an additional €5 million to industrialize production. Its immediate plan is to launch manufacturing at a rate of several hundred units per month. The new funding is intended to support that production ramp.

Led · Equity · Feb 2026

AFYREN develops bio-based, low-carbon ingredients through innovative fermentation technology for use in sustainable industrial applications. The company is investing in its flagship AFYREN NEOXY biorefinery, which it now fully owns and is upgrading through an ongoing investment program. AFYREN has secured public support for these investments, including a €3 million grant from the Grand Est Region supported by the European Just Transition Fund and prior installments under Bpifrance’s France Relance initiative. Management says the investments aim to reinforce industrial assets, create jobs, and build sustainable skills in the region. The company announced it met the milestones required to obtain the final grant installment, and previously received a €2.2 million final installment in March 2026 under the same program.

Led · Series A · Jan 2026

BrightHeart offers the B-Right AI Platform, a suite of FDA-cleared software tools that integrate directly into routine prenatal ultrasound machines to guide clinicians through complete fetal exams, with a particular focus on accurate, early detection of congenital heart defects (CHD). The technology provides step-by-step imaging guidance, automated organ tracking and real-time diagnostic support, helping OB-GYNs perform faster, more complete and more confident evaluations. Peer-reviewed studies in Obstetrics & Gynecology report the platform can raise CHD detection rates above 96 % while reducing diagnostic errors. To date, the company has secured five FDA clearances and partnerships with leading academic centers, underscoring a solid regulatory and clinical foundation. Fresh capital will fund commercial launch in the United States, broaden European deployment and accelerate continued product innovation. BrightHeart positions itself as a global standard setter in prenatal imaging by embedding advanced AI into everyday clinical workflows.